Macular Telangiectasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major macular telangiectasia markets are expected to exhibit a CAGR of 6.7% during 2024-2034.
The macular telangiectasia market has been comprehensively analyzed in IMARC's new report titled "Macular Telangiectasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Macular telangiectasia, also known as MacTel, is a rare, progressive eye disorder that affects the macula, the central area of the retina responsible for sharp, detailed vision. This condition is characterized by the development of abnormal, dilated blood vessels (telangiectasia) within the macula, leading to a range of visual disturbances. Individuals suffering from the ailment often experience symptoms, such as blurred or distorted central vision, difficulty reading, and an increased sensitivity to glare. As the disorder advances, central vision loss can progressively worsen, impacting daily activities like driving and recognizing faces. The diagnosis of macular telangiectasia typically involves a comprehensive eye examination, including optical coherence tomography (OCT) to visualize the retinal layers and identify characteristic changes within the macula. Fluorescein angiography may also be used to highlight abnormal blood vessels and their leakage patterns. Since macular telangiectasia shares symptoms with various other retinal conditions, accurate diagnosis is crucial to guide appropriate management and treatment options.
The increasing cases of vascular dysfunction that can result in abnormal dilation and leakage of the blood vessels, causing damage to the retinal tissue, are primarily driving the macular telangiectasia market. In addition to this, the inflating utilization of pharmacological interventions, including anti-VEGF agents and corticosteroids, to inhibit blood vessel growth and reduce inflammation is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical options like vitrectomy, which involves the removal of vitreous gel to access the retina for repair, is further bolstering the market growth. Apart from this, the rising usage of precision medicine techniques, such as genetic profiling and molecular diagnostics, to tailor treatment strategies according to individual patients' genetic makeup is acting as another significant growth-inducing factor. Additionally, the emerging popularity of assistive devices, including electronic magnifiers for low vision aids, on account of their various benefits, like minimal discomfort and an improved standard of living for individuals suffering from the illness, is also augmenting the market growth. Furthermore, the escalating demand for targeted gene therapies that aim to replace or correct the malfunctioning genes responsible for vascular abnormalities in the retina is expected to drive the macular telangiectasia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the macular telangiectasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for macular telangiectasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the macular telangiectasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the macular telangiectasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the macular telangiectasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current macular telangiectasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the macular telangiectasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the macular telangiectasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the macular telangiectasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of macular telangiectasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of macular telangiectasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of macular telangiectasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with macular telangiectasia across the seven major markets?
What is the size of the macular telangiectasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of macular telangiectasia?
What will be the growth rate of patients across the seven major markets?
Macular Telangiectasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for macular telangiectasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the macular telangiectasia market?
What are the key regulatory events related to the macular telangiectasia market?
What is the structure of clinical trial landscape by status related to the macular telangiectasia market?
What is the structure of clinical trial landscape by phase related to the macular telangiectasia market?
What is the structure of clinical trial landscape by route of administration related to the macular telangiectasia market?
The macular telangiectasia market has been comprehensively analyzed in IMARC's new report titled "Macular Telangiectasia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Macular telangiectasia, also known as MacTel, is a rare, progressive eye disorder that affects the macula, the central area of the retina responsible for sharp, detailed vision. This condition is characterized by the development of abnormal, dilated blood vessels (telangiectasia) within the macula, leading to a range of visual disturbances. Individuals suffering from the ailment often experience symptoms, such as blurred or distorted central vision, difficulty reading, and an increased sensitivity to glare. As the disorder advances, central vision loss can progressively worsen, impacting daily activities like driving and recognizing faces. The diagnosis of macular telangiectasia typically involves a comprehensive eye examination, including optical coherence tomography (OCT) to visualize the retinal layers and identify characteristic changes within the macula. Fluorescein angiography may also be used to highlight abnormal blood vessels and their leakage patterns. Since macular telangiectasia shares symptoms with various other retinal conditions, accurate diagnosis is crucial to guide appropriate management and treatment options.
The increasing cases of vascular dysfunction that can result in abnormal dilation and leakage of the blood vessels, causing damage to the retinal tissue, are primarily driving the macular telangiectasia market. In addition to this, the inflating utilization of pharmacological interventions, including anti-VEGF agents and corticosteroids, to inhibit blood vessel growth and reduce inflammation is also creating a positive outlook for the market. Moreover, the widespread adoption of surgical options like vitrectomy, which involves the removal of vitreous gel to access the retina for repair, is further bolstering the market growth. Apart from this, the rising usage of precision medicine techniques, such as genetic profiling and molecular diagnostics, to tailor treatment strategies according to individual patients' genetic makeup is acting as another significant growth-inducing factor. Additionally, the emerging popularity of assistive devices, including electronic magnifiers for low vision aids, on account of their various benefits, like minimal discomfort and an improved standard of living for individuals suffering from the illness, is also augmenting the market growth. Furthermore, the escalating demand for targeted gene therapies that aim to replace or correct the malfunctioning genes responsible for vascular abnormalities in the retina is expected to drive the macular telangiectasia market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the macular telangiectasia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for macular telangiectasia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the macular telangiectasia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the macular telangiectasia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the macular telangiectasia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current macular telangiectasia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the macular telangiectasia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the macular telangiectasia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the macular telangiectasia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of macular telangiectasia across the seven major markets?
What is the number of prevalent cases (2018-2034) of macular telangiectasia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of macular telangiectasia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with macular telangiectasia across the seven major markets?
What is the size of the macular telangiectasia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of macular telangiectasia?
What will be the growth rate of patients across the seven major markets?
Macular Telangiectasia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for macular telangiectasia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the macular telangiectasia market?
What are the key regulatory events related to the macular telangiectasia market?
What is the structure of clinical trial landscape by status related to the macular telangiectasia market?
What is the structure of clinical trial landscape by phase related to the macular telangiectasia market?
What is the structure of clinical trial landscape by route of administration related to the macular telangiectasia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MACULAR TELANGIECTASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MACULAR TELANGIECTASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MACULAR TELANGIECTASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 MACULAR TELANGIECTASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MACULAR TELANGIECTASIA - UNMET NEEDS
10 MACULAR TELANGIECTASIA - KEY ENDPOINTS OF TREATMENT
11 MACULAR TELANGIECTASIA - MARKETED PRODUCTS
11.1 List of Macular Telangiectasia Marketed Drugs Across the Top 7 Markets
11.1 List of Amblyopia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MACULAR TELANGIECTASIA - PIPELINE DRUGS
12.1 List of Macular Telangiectasia Pipeline Drugs Across the Top 7 Markets
12.1.1 NT 501 - Neurotech Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 MACULAR TELANGIECTASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 MACULAR TELANGIECTASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MACULAR TELANGIECTASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Macular Telangiectasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Macular Telangiectasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Macular Telangiectasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Macular Telangiectasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Macular Telangiectasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Macular Telangiectasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Macular Telangiectasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Macular Telangiectasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Macular Telangiectasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Macular Telangiectasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Macular Telangiectasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Macular Telangiectasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Macular Telangiectasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Macular Telangiectasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Macular Telangiectasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Macular Telangiectasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Macular Telangiectasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Macular Telangiectasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Macular Telangiectasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Macular Telangiectasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Macular Telangiectasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Macular Telangiectasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Macular Telangiectasia - Access and Reimbursement Overview
16 MACULAR TELANGIECTASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MACULAR TELANGIECTASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MACULAR TELANGIECTASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 MACULAR TELANGIECTASIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 MACULAR TELANGIECTASIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 MACULAR TELANGIECTASIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 MACULAR TELANGIECTASIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 MACULAR TELANGIECTASIA - UNMET NEEDS
10 MACULAR TELANGIECTASIA - KEY ENDPOINTS OF TREATMENT
11 MACULAR TELANGIECTASIA - MARKETED PRODUCTS
11.1 List of Macular Telangiectasia Marketed Drugs Across the Top 7 Markets
11.1 List of Amblyopia Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 MACULAR TELANGIECTASIA - PIPELINE DRUGS
12.1 List of Macular Telangiectasia Pipeline Drugs Across the Top 7 Markets
12.1.1 NT 501 - Neurotech Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13 MACULAR TELANGIECTASIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 MACULAR TELANGIECTASIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 MACULAR TELANGIECTASIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Macular Telangiectasia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Macular Telangiectasia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Macular Telangiectasia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Macular Telangiectasia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Macular Telangiectasia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Macular Telangiectasia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Macular Telangiectasia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Macular Telangiectasia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Macular Telangiectasia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Macular Telangiectasia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Macular Telangiectasia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Macular Telangiectasia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Macular Telangiectasia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Macular Telangiectasia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Macular Telangiectasia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Macular Telangiectasia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Macular Telangiectasia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Macular Telangiectasia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Macular Telangiectasia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Macular Telangiectasia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Macular Telangiectasia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Macular Telangiectasia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Macular Telangiectasia - Access and Reimbursement Overview
16 MACULAR TELANGIECTASIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 MACULAR TELANGIECTASIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 MACULAR TELANGIECTASIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
